Fig 1.

Protocol‐specified AE management in cohorts 1 + 2 and cohort 4 of ZUMA‐1. (A) Comparison of AE management in cohorts 1 + 2 and cohort 4 of ZUMA‐1. ‘Yes’ or ‘No’ indicates whether tocilizumab or corticosteroid was or was not administered, respectively. (B) Tocilizumab and corticosteroid guidelines for AE management in cohort 4 of ZUMA‐1. *Only in case of comorbidities or older age. ^†Only if no improvement with tocilizumab; use standard dose. ^‡If no improvement after three days. ^§Therapy to be tapered upon improvement of symptoms at investigator’s discretion. ^||Not to exceed 800 mg. AE, adverse event; CRS, cytokine release syndrome; HD, high dose; IV, intravenously; N/A, not applicable; NE, neurologic event; Mgmt, management.